Mineralys Therapeutics, Inc. SEC filings MLYS

Mineralys Therapeutics, Inc. has 408 filings in SEC EDGAR's recent list, going back to Jun 13, 2022. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, officer or director change). The company's fiscal year ends on December 31.

Mineralys Therapeutics, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report
Results of operations, Officer or director change
Nov 4, 2026 Oct 29, 2026
8-K Current report
Material agreement, Agreement ended
Oct 29, 2026 Oct 27, 2026
4 Insider transaction Oct 20, 2026 Oct 19, 2026
3 Initial insider ownership Oct 20, 2026 Oct 19, 2026
4 Insider transaction Oct 20, 2026 Oct 19, 2026
3 Initial insider ownership Oct 20, 2026 Oct 19, 2026
8-K Current report
Officer or director change
Oct 19, 2026 Oct 16, 2026
144 Notice of proposed sale Oct 13, 2026 —
4 Insider transaction Oct 2, 2026 Sep 30, 2026
144 Notice of proposed sale Sep 30, 2026 —
4 Insider transaction Sep 24, 2026 Sep 22, 2026
4 Insider transaction Sep 22, 2026 Sep 21, 2026
144 Notice of proposed sale Sep 22, 2026 —
144 Notice of proposed sale Sep 21, 2026 —
4 Insider transaction Sep 17, 2026 Sep 15, 2026
144 Notice of proposed sale Sep 17, 2026 —
144 Notice of proposed sale Sep 15, 2026 —
144 Notice of proposed sale Sep 14, 2026 —
144 Notice of proposed sale Sep 9, 2026 —
4 Insider transaction Aug 25, 2026 Aug 21, 2026
144 Notice of proposed sale Aug 21, 2026 —
144 Notice of proposed sale Aug 17, 2026 —
144 Notice of proposed sale Aug 13, 2026 —
4 Insider transaction Aug 12, 2026 Aug 10, 2026
3 Initial insider ownership Aug 12, 2026 Aug 10, 2026
4 Insider transaction Aug 12, 2026 Aug 10, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations, Officer or director change
Aug 11, 2026 Aug 5, 2026
144 Notice of proposed sale Aug 10, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 6, 2026 —
4 Insider transaction Jul 23, 2026 Jul 21, 2026
144 Notice of proposed sale Jul 21, 2026 —
4 Insider transaction Jul 20, 2026 Jul 17, 2026
144 Notice of proposed sale Jul 17, 2026 —
4 Insider transaction Jul 15, 2026 Jul 13, 2026
4 Insider transaction Jul 15, 2026 Jul 13, 2026
144 Notice of proposed sale Jul 15, 2026 —
144/A Filing Jul 14, 2026 —
144 Notice of proposed sale Jul 13, 2026 —
144 Notice of proposed sale Jul 13, 2026 —
4 Insider transaction Jul 10, 2026 Jul 9, 2026
144 Notice of proposed sale Jul 9, 2026 —
4 Insider transaction Jun 30, 2026 Jun 30, 2026
4 Insider transaction Jun 30, 2026 Jun 26, 2026
144 Notice of proposed sale Jun 30, 2026 —
144 Notice of proposed sale Jun 29, 2026 —
4 Insider transaction Jun 17, 2026 Jun 15, 2026
4 Insider transaction Jun 17, 2026 Jun 17, 2026
144 Notice of proposed sale Jun 17, 2026 —
144 Notice of proposed sale Jun 17, 2026 —
144 Notice of proposed sale Jun 15, 2026 —
4 Insider transaction Jun 12, 2026 Jun 10, 2026
144 Notice of proposed sale Jun 12, 2026 —
144 Notice of proposed sale Jun 10, 2026 —
8-K Current report
Other events
Jun 3, 2026 Jun 3, 2026
424B5 Prospectus supplement Jun 3, 2026 —
8-K Current report
Material agreement, New debt
Jun 3, 2026 Jun 2, 2026
8-K Current report
Shareholder vote results
May 22, 2026 May 21, 2026
4 Insider transaction May 19, 2026 May 18, 2026
144 Notice of proposed sale May 18, 2026 —
4 Insider transaction May 13, 2026 May 11, 2026
144 Notice of proposed sale May 13, 2026 —
144 Notice of proposed sale May 12, 2026 —
144 Notice of proposed sale May 11, 2026 —
10-Q Quarterly report May 6, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 6, 2026 May 6, 2026
4 Insider transaction Apr 21, 2026 Apr 17, 2026
144 Notice of proposed sale Apr 17, 2026 —
4 Insider transaction Apr 15, 2026 Apr 13, 2026
4 Insider transaction Apr 15, 2026 Apr 13, 2026
144 Notice of proposed sale Apr 15, 2026 —
4 Insider transaction Apr 13, 2026 Apr 9, 2026
144 Notice of proposed sale Apr 13, 2026 —
144 Notice of proposed sale Apr 13, 2026 —
ARS Annual report to shareholders Apr 10, 2026 Dec 31, 2025
144 Notice of proposed sale Apr 9, 2026 —
DEFA14A Additional proxy material Apr 8, 2026 —
DEF 14A Proxy statement Apr 8, 2026 May 21, 2026
4 Insider transaction Apr 2, 2026 Mar 31, 2026
4 Insider transaction Apr 2, 2026 Mar 31, 2026
144 Notice of proposed sale Mar 31, 2026 —
144 Notice of proposed sale Mar 31, 2026 —
4 Insider transaction Mar 31, 2026 Mar 27, 2026
144 Notice of proposed sale Mar 17, 2026 —
4 Insider transaction Mar 17, 2026 Mar 17, 2026
4 Insider transaction Mar 16, 2026 Mar 12, 2026
144 Notice of proposed sale Mar 13, 2026 —
10-K Annual report Mar 12, 2026 Dec 31, 2025
144 Notice of proposed sale Mar 12, 2026 —
8-K Current report
Results of operations
Mar 12, 2026 Mar 12, 2026
4 Insider transaction Mar 10, 2026 Mar 9, 2026
144 Notice of proposed sale Mar 9, 2026 —
8-K Current report
Regulation FD disclosure, Other events
Mar 9, 2026 Mar 6, 2026
3 Initial insider ownership Mar 4, 2026 Mar 4, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 20, 2026 Feb 19, 2026
4 Insider transaction Feb 17, 2026 Feb 17, 2026
144 Notice of proposed sale Feb 17, 2026 —
4 Insider transaction Feb 13, 2026 Feb 12, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 13, 2026 —
144 Notice of proposed sale Feb 13, 2026 —
S-8 Employee stock plan registration Feb 13, 2026 —
144 Notice of proposed sale Feb 12, 2026 —
4 Insider transaction Feb 11, 2026 Feb 9, 2026
144 Notice of proposed sale Feb 9, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 5, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Jan 21, 2026 —
4 Insider transaction Jan 20, 2026 Jan 20, 2026
144 Notice of proposed sale Jan 20, 2026 —
4 Insider transaction Jan 15, 2026 Jan 13, 2026
144 Notice of proposed sale Jan 14, 2026 —
4 Insider transaction Jan 13, 2026 Jan 12, 2026
4 Insider transaction Jan 13, 2026 Jan 12, 2026
4 Insider transaction Jan 13, 2026 Jan 9, 2026
144 Notice of proposed sale Jan 13, 2026 —
144 Notice of proposed sale Jan 12, 2026 —
144 Notice of proposed sale Jan 12, 2026 —
144 Notice of proposed sale Jan 12, 2026 —
144 Notice of proposed sale Jan 9, 2026 —
4 Insider transaction Jan 6, 2026 Jan 2, 2026
8-K Current report
Regulation FD disclosure, Other events
Jan 6, 2026 Jan 6, 2026
144 Notice of proposed sale Jan 2, 2026 —
4 Insider transaction Nov 24, 2025 Nov 21, 2025
4 Insider transaction Nov 21, 2025 Nov 20, 2025
144 Notice of proposed sale Nov 20, 2025 —
4 Insider transaction Nov 13, 2025 Nov 11, 2025
4 Insider transaction Nov 13, 2025 Nov 11, 2025
4 Insider transaction Nov 13, 2025 Nov 13, 2025
4 Insider transaction Nov 13, 2025 Nov 11, 2025
144 Notice of proposed sale Nov 13, 2025 —
144 Notice of proposed sale Nov 13, 2025 —
144 Notice of proposed sale Nov 12, 2025 —
144 Notice of proposed sale Nov 12, 2025 —
S-3ASR Automatic shelf registration Nov 10, 2025 —
10-Q Quarterly report Nov 10, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 10, 2025 Nov 10, 2025
4 Insider transaction Oct 15, 2025 Oct 13, 2025
4 Insider transaction Oct 15, 2025 Oct 13, 2025
4 Insider transaction Oct 15, 2025 Oct 15, 2025
144 Notice of proposed sale Oct 15, 2025 —
144 Notice of proposed sale Oct 14, 2025 —
144 Notice of proposed sale Oct 14, 2025 —
4 Insider transaction Sep 16, 2025 Sep 15, 2025
144 Notice of proposed sale Sep 15, 2025 —
4 Insider transaction Sep 8, 2025 Sep 4, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Sep 8, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Sep 8, 2025 —
4 Insider transaction Sep 8, 2025 Sep 4, 2025
8-K Current report
Other events
Sep 3, 2025 Sep 2, 2025
424B5 Prospectus supplement Sep 3, 2025 —
S-3MEF Filing Sep 2, 2025 —
8-K Current report
Other events
Sep 2, 2025 Sep 2, 2025
424B5 Prospectus supplement Sep 2, 2025 —
4 Insider transaction Aug 14, 2025 Aug 12, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
144 Notice of proposed sale Aug 13, 2025 —
10-Q Quarterly report Aug 12, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 12, 2025 Aug 12, 2025
4 Insider transaction Jul 30, 2025 Jul 28, 2025
144 Notice of proposed sale Jul 30, 2025 —
144 Notice of proposed sale Jul 30, 2025 —
144 Notice of proposed sale Jul 28, 2025 —
4 Insider transaction Jul 15, 2025 Jul 11, 2025
4 Insider transaction Jul 15, 2025 Jul 11, 2025
4 Insider transaction Jul 15, 2025 Jul 14, 2025
144 Notice of proposed sale Jul 14, 2025 —
144 Notice of proposed sale Jul 11, 2025 —
144 Notice of proposed sale Jul 11, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Jun 17, 2025 Jun 17, 2025
4 Insider transaction Jun 16, 2025 Jun 12, 2025
144 Notice of proposed sale Jun 13, 2025 —
8-K Current report
Shareholder vote results
May 22, 2025 May 22, 2025
4 Insider transaction May 15, 2025 May 14, 2025
144 Notice of proposed sale May 14, 2025 —
4 Insider transaction May 13, 2025 May 12, 2025
10-Q Quarterly report May 12, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 12, 2025 May 12, 2025
4 Insider transaction Apr 25, 2025 Mar 13, 2025
4 Insider transaction Apr 15, 2025 Apr 14, 2025
4 Insider transaction Apr 15, 2025 Apr 11, 2025
4 Insider transaction Apr 15, 2025 Apr 11, 2025
144 Notice of proposed sale Apr 14, 2025 —
144 Notice of proposed sale Apr 11, 2025 —
144 Notice of proposed sale Apr 11, 2025 —
ARS Annual report to shareholders Apr 9, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 9, 2025 —
DEF 14A Proxy statement Apr 9, 2025 May 22, 2025
4 Insider transaction Apr 3, 2025 Apr 1, 2025
144 Notice of proposed sale Apr 1, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Mar 31, 2025 Mar 29, 2025

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MLYS (Nasdaq)
Fiscal year ends
December 31
Headquarters
Radnor, PA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1933414

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.